PGEN · Precigen Inc
United States · RS rating 43 · As of 2026-11-03
| Price | 5.25 USD |
|---|---|
| 1-day change | +2.1% |
| RS rating (overall / 1M / 3M / 12M) | 43 / 11 / 27 / 73 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 40 / 35 / 29 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | – |
| Sales growth Q/Q | +56.2% |
| Distance from 52-week high | +38.7% |
| Market cap (USD) | $1.4B |